naltrexone and semaglutide Wegovy Ozempic (semaglutide) are associated with a 50-56% reduction in alcohol addiction Explore Low Dose Naltrexone (LDN)

DOI: 10.1007/978-3-030-32300-4 81

Tirzepatide is the newest FDA-approved prescription medication that helps treat type 2 diabetes and obesity

In a statement, Wegovy's maker Novo Nordisk said it was "encouraged" by the new guidance from CMS but said it hopes to see Part D coverage expanded for "obesity medicines when used for chronic weight management." The drug maker is among those pushing for Congress to expand coverage of treatments for obesity

This absence of data makes it challenging to identify predictors of severe disease, underscoring the urgent need for comprehensive longitudinal research in this population